黑料不打烊

Global Endometrial Cancer Market Trends and Insights

Rising Prevalence Linked to Obesity and Aging Women

The endometrial cancer market is supported by risk factors that are not likely to reverse quickly. Historical U.S. incidence data show an upward pattern, and excess estrogen produced by adipose tissue is a key biological link between obesity and disease risk. The Lancet projected that total global cancer incidence will reach 30.5 million cases by 2050, 60.7% higher than in 2024.^{[1]H. Sung et al., “Global Cancer Burden and Forecasts to 2050,” The Lancet, thelancet.com} Endometrial cancer is concentrated among postmenopausal women aged 60 to 74, making aging populations especially relevant to care demand. Evidence also indicates rising incidence among younger women. Younger patients may have different insurance coverage and treatment uptake than older populations, which broadens demand across the endometrial cancer market.

Rapid Adoption of Immunotherapy-Chemotherapy Combinations

The endometrial cancer market is being reshaped by a rapid change in first-line treatment for advanced and recurrent disease. Merck received U.S. approval in June 2024 for pembrolizumab with carboplatin and paclitaxel for adult patients with primary advanced or recurrent endometrial carcinoma, regardless of mismatch repair status.^{[2]Merck & Co., Inc., “FDA Approves Merck’s KEYTRUDA Plus Carboplatin and Paclitaxel for Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma,” Merck, merck.com} A 2026 meta-analysis of 10 randomized trials involving 4,052 patients found median progression-free survival of 14.6 months with PD-1 or PD-L1 inhibitors plus chemotherapy, compared with 10.2 months with chemotherapy alone.^{[3]L. Zhang et al., “PD-1/PD-L1 Inhibitors Plus Chemotherapy as First-Line Therapy for Advanced or Metastatic Endometrial Cancer,” Frontiers in Immunology, frontiersin.org} It also reported median overall survival of 43.7 months compared with 29.1 months, raising the clinical standard for later entrants in the endometrial cancer market.

Favorable Reimbursement for Targeted Therapies

Coverage decisions can expand the endometrial cancer market when approved therapies are paired with clear diagnostic and treatment pathways. Guideline adoption of pembrolizumab and dostarlimab has supported commercial coverage in the United States, though patient access remains dependent on trial criteria and insurer policy. The FDA-approved OncoMate MSI Dx system established a companion diagnostic route for the lenvatinib and pembrolizumab treatment approach. Molecular profiling is increasingly important because treatment selection depends on mismatch repair and other tumor characteristics. The 2025 ESGO-ESTRO-ESP guideline update incorporated the revised FIGO molecular staging framework, further connecting diagnostic capability with treatment decisions. The endometrial cancer industry, therefore, depends on reimbursement, laboratory capacity, and clinical use of molecular classification rather than regulatory approval alone.

Growth in Minimally Invasive Diagnostic Procedures

The endometrial cancer market is also changing as diagnosis and surgery shift toward less invasive care. A Mayo Clinic study of tampon-based sample collection and methylated DNA markers reported 82% sensitivity and 96% specificity for detection in vaginal fluid, with an area under the curve of 0.9. This approach may offer a less burdensome option than office hysteroscopy for symptomatic patients. It may be especially relevant for older women and women who experience discomfort with invasive procedures. Molecular profiling can also improve treatment selection after diagnosis, because it identifies patients who may avoid unnecessary radiotherapy. These changes move parts of the diagnostic pathway toward outpatient care and create a different revenue mix within the endometrial cancer market.

High Treatment Costs of Novel Agents

High prices can limit the endometrial cancer market even when clinical evidence is strong. A 2025 cost-effectiveness analysis found an incremental cost-effectiveness ratio of USD 220,259 per quality-adjusted life-year for pembrolizumab plus chemotherapy in mismatch repair proficient patients in China. The same analysis reported USD 70,207 per quality-adjusted life-year in mismatch repair-deficient patients. A separate 2025 analysis found that durvalumab pricing would need a 90% reduction to meet its modeled cost-effectiveness threshold for mismatch repair-deficient disease in the United States. In France, the Haute Autorité de Santé estimated a 3-year budget impact of EUR 429 million, equivalent to USD 471 million, for dostarlimab in an estimated 14,540 patients. These findings show why price negotiations and reimbursement rules can delay adoption in the endometrial cancer market.

Drug-Related Toxicities Limiting Adherence

Treatment-related adverse events can slow the use of combination regimens in the endometrial cancer market. A 2025 meta-analysis found that immunotherapy with chemotherapy increased grade 3 to 5 adverse events by 11% compared with chemotherapy alone, with diarrhea and anemia among the more frequent serious toxicities. The same evidence base identified higher fatigue rates in the combination setting. Discontinuation affects treatment value in routine care because patients may not receive the duration achieved in clinical studies. HER2-targeting antibody-drug conjugates also require monitoring for drug-related interstitial lung disease. Anti-emetic protocols, dose modification, and patient selection may improve adherence, but their use differs across health systems.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Offering: Services Dominate While Therapeutics Drives Value Growth

Services held 73.77% of the market share in 2025 because most patients need diagnosis, surgery, radiation, and follow-up before systemic therapy. Diagnostic services include biopsy, pelvic and transvaginal ultrasound, hysteroscopy, and computed tomography. These services establish disease presence, stage, and treatment planning. Surgical services remain essential because hysterectomy is central to the care of many patients with localized disease. Radiotherapy services provide adjuvant care and management for selected recurrent cases. The service mix remains broad because the disease pathway spans screening, diagnosis, treatment, and surveillance.

Therapeutics is projected to grow at a 6.59% CAGR through 2031, above the overall endometrial cancer market growth rate. Immunotherapy now has a larger role in advanced disease following the 2024 approvals of pembrolizumab, durvalumab, and dostarlimab combinations. Chemotherapy remains part of the treatment backbone because carboplatin and paclitaxel are used with the approved checkpoint inhibitors. Targeted therapy is gaining relevance for molecularly defined tumors and for patients with recurrent disease. The therapeutics segment, therefore, concentrates much of the endometrial cancer market’s future value growth.

By Type of Cancer: Endometrioid Adenocarcinoma Anchors Volumes, Rare Subtypes Attract Pipeline Interest

Endometrioid adenocarcinoma held 73.26% of the market share in 2025 and remains the largest cancer-type segment. It is the most common histologic form and is often low-grade at diagnosis. Many patients are diagnosed at an early stage, which supports the continuing role of surgery and radiation services. Carcinosarcoma is less common but clinically aggressive and requires specialized treatment decisions. Squamous cell carcinoma of the endometrium is rare and has limited dedicated trial evidence. Clinical teams often apply evidence from broader endometrial cancer regimens when managing rare histologies. This clinical diversity sustains demand for pathology, molecular testing, and specialist oncology care within the endometrial cancer market.

The other segment is forecasted to grow at a 6.63% CAGR from 2026 to 2031, making it the fastest-growing cancer-type segment. It includes rarer histologies such as serous carcinoma and clear-cell variants. The segment is attracting pipeline activity because HER2 and TROP2 may provide actionable targets in selected tumors. BioNTech and DualityBio reported a 47.9% confirmed objective response rate for trastuzumab pamirtecan in a Phase 2 cohort of patients with HER2-expressing recurrent endometrial cancer. Daiichi Sankyo started the global Phase 3 DESTINY-Endometrial01 trial in June 2025 for trastuzumab deruxtecan in HER2-expressing mismatch repair proficient disease. These programs show why rare histologies have become an important development area in the endometrial cancer market.

By Care Delivery Setting: Hospitals Lead, but Ambulatory Surgical Centers Capture Outpatient Volume Migration

Hospitals held 45.92% of the market share in 2025 because they provide complex surgery, lymph node assessment, inpatient infusion, and multidisciplinary care. Academic and National Cancer Institute-designated cancer centers are important within this setting. They manage complex cases and coordinate pathology, surgery, radiation, and systemic therapy. Community hospitals also deliver a large share of routine surgery and adjuvant treatment. Cancer treatment centers and specialty oncology or gynecology clinics provide focused care outside the traditional hospital structure. The endometrial cancer market, therefore, continues to rely on hospital infrastructure for complex disease pathways. 

Ambulatory surgical centers are projected to grow at a 6.34% CAGR through 2031 as selected procedures move into outpatient settings. Shorter schedules can reduce the practical burden of treatment for patients and providers. The shift toward sentinel lymph node dissection also reduces surgical complexity compared with complete lymphadenectomy. These changes can support outpatient treatment when patients meet clinical criteria. The endometrial cancer market may therefore see a gradual redistribution of lower-acuity care across ambulatory settings.

Geography Analysis

North America held 41.29% of the market share in 2025 and remains the largest regional contributor. The region benefits from dense oncology infrastructure, established reimbursement systems, and broad availability of approved immunotherapies. The United States has a high disease burden associated with obesity, and the American Cancer Society reported mortality rates of 9.0 per 100,000 among Black women and 4.6 per 100,000 among White women. Canada and Mexico add demand through their public and private oncology systems. The endometrial cancer market in North America remains shaped by differences in insurance coverage, specialist access, and molecular testing.

Europe is a major treatment region, led by Germany, France, the United Kingdom, Italy, and Spain. The 2025 ESGO-ESTRO-ESP update integrated the revised FIGO molecular staging framework into clinical management, supporting more tailored adjuvant treatment and molecular classification. European Medicines Agency approvals do not ensure immediate national reimbursement. The French assessment for dostarlimab reported an incremental cost-effectiveness ratio of EUR 150,697 per quality-adjusted life-year, equivalent to USD 165,000, and a 3-year budget impact of EUR 429 million, equivalent to USD 471 million. Eastern European markets face greater infrastructure and pricing constraints, which lengthen adoption timelines.

Asia-Pacific is projected to grow at a 5.90% CAGR through 2031, the fastest regional rate in the endometrial cancer market. Japan approved pembrolizumab with chemotherapy in December 2024, while AstraZeneca Japan received approval for Imfinzi and Lynparza in November 2024. South Korea has approvals in place, but reimbursement remains a key barrier, while China’s domestic oncology manufacturing base and real-world evidence pathway can support faster regulatory activity. The high modeled cost-effectiveness ratio for pembrolizumab in mismatch repair proficient disease creates pressure for price negotiations, and the Middle East, Africa, and South America remain price-sensitive opportunities with longer access cycles.